A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Latest Information Update: 05 Nov 2026
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary) ; Ustekinumab; Ustekinumab
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms GALAXI; GALAXI 1; GALAXI 2; GALAXI 3
- Sponsors Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Innovative Medicine
Most Recent Events
- 19 Oct 2026 According to Johnson & Johnson Biotech Media Release, data from this study were presented at the 2026 United European Gastroenterology Week (UEG Week).
- 19 Oct 2026 Results presented in a Johnson & Johnson Media Release.
- 12 Oct 2026 Results presented in the Johnson & Johnson media release.